Company / Total Debt
NeoGenomics Laboratories, Inc. Total Debt History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$341.9M
FY2025
5-year range
$341.9M / $541.1M
FY2021-FY2025
Trend
-36.8%
vs FY2024
Sector context
#70 of 100
Health Care
What the data says
At $342M, NeoGenomics Laboratories, Inc.'s total debt ranks #31 of 100 in the Health Care sector. Improved from $538M to $342M over the past 2 years.
Based on SEC 10-K filings.
$342M in FY2025.
Improved from $538M to $342M over the past 2 years.
Health Care sector context is included.
Total Debt over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#31 of 100 in Health CareTop 30% of 100This company $341.9M Sector average $4.6B
▼
-92.5% below sector average
Key checks
Key Insights
- In FY2025, total debt decreased 36.8% year-over-year.
- Ranks #70 out of 100 companies in the Health Care sector.
- Peak total debt was recorded in FY2024.
- Lowest total debt in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 0.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $341.9M | -36.8% |
| FY2024 | $541.1M | +0.5% |
| FY2023 | $538.2M | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | $101.8M | +5.3% |
| FY2017 | $96.7M | -1.3% |
| FY2016 | $97.9M | +77.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026